Documents to download

Dementia Infographic – Public Health England

Dementia is a syndrome characterised by progressive damage to nerve cells in the brain causing loss of cognitive function. Symptoms worsen over time and 24-hour care is needed in the latter stages.

At least 800,000 people in the UK have dementia and it costs £26.3bn per year in health and social care costs (fig 1), more than cancer and heart disease combined. The number of people with dementia and associated costs are predicted to more than double by 2050.

There are no licensed drugs that stop or slow the progression of dementia. UK Dementia policy in recent years has resulted in increased funding to advance treatment and care. Find out more about the Government’s approach to tackling dementia on its dementia topic page.

The key points in this POSTnote are:

  • Current drug treatments marginally alleviate symptoms. Psychosocial interventions provide valuable support but access o them is patchy.
  • The development of drugs that address the underlying diseases is challenging due to their complexity.
  • Investing in research and development on dementia drugs is financially risky for the pharmaceutical industry. Drug development is an expensive and slow process and there has been a high failure rate in developing drugs. as they fail to yield positive results during clinical trials.
  • Understanding dementia requires analysis of large amounts of data and therefore a collaborative approach. A robust regulatory and legal framework is needed for privacy, data access and data standardisation so that study outputs can be shared.
  • There are new UK and international initiatives working to accelerate research and support collaboration. There are over ten potential disease-modifying drugs in development that may be available in the next five years. Stakeholders call for continued funding to ensure that the value of current investment is realised.
  • The first disease-modifying drug will be expensive and will not treat all types of dementia. There is growing consensus that treatment needs to start as early as possible, potentially even before symptoms emerge. Clinical implementation will be practically and ethically complex.
  • A healthy and active lifestyle may reduce an individual risk of developing dementia. While further research is needed, improving public health could reduce the number of new cases in the long term.

Documents to download

Related posts

  • Advances in vaccine technologies

    This POSTnote provides an overview of vaccine development and technologies. It also covers opportunities and challenges to vaccine discovery and manufacture, as well as policy approaches to stimulate vaccine research and development (R&D) in the UK.

    Advances in vaccine technologies
  • Smart Cities

    "Smart cities" describes places that incorporate a range of technologies (especially those that collect and use data) to address economic, social, and environmental challenges. Projects usually take place in urban areas, but are also deployed in rural settings. This POSTnote looks at smart city innovation in the UK and the technologies involved. It considers the factors driving the adoption of smart city technologies, and the potential benefits, barriers and risks associated with their implementation.

    Smart Cities
  • Children’s Mental Health and the COVID-19 Pandemic

    A POSTnote describing the impact of the COVID-19 pandemic on children's mental health. This briefing summarises the latest understanding from research about the effects on children throughout the pandemic, and the factors that increase vulnerability to poor mental health. It also reviews policy approaches that seek to protect children's mental health, with particular focus on recent initiatives to address this.

    Children’s Mental Health and the COVID-19 Pandemic